Michael Maldonado, OD
Optometrist · El Paso, TXNPI 1437333929
Payments from drug & device makers
Across 57 payments — averaging $111.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Carl Zeiss Meditec, Inc.$1K
- AbbVie$606
- Sun Pharmaceutical Industries Inc.$605
- Alcon$473
- Dompe US, Inc.$260
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,87529%
- Food & beverage$4,49671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 7 | $1,528 |
| Carl Zeiss Meditec, Inc. | 4 | $1,032 |
| AbbVie(2 entities) | 8 | $606 |
| Sun Pharmaceutical Industries Inc. | 10 | $605 |
| Alcon | 4 | $473 |
| Dompe US, Inc. | 3 | $260 |
| Regeneron | 2 | $241 |
| Aerie Pharmaceuticals, Inc. | 2 | $235 |
| Johnson & Johnson Vision Care, Inc. | 2 | $219 |
| Oyster Point Pharma, Inc. | 2 | $214 |
| Rxsight Inc | 1 | $131 |
| Novartis | 1 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $105 |
| LKC Technologies, Inc. | 1 | $98 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $92 |
| Coopervision Inc. | 1 | $91 |
| Eyevance Pharmaceuticals LLC | 1 | $79 |
| ABB Con-cise Optical Group LLC | 1 | $75 |
| Bausch & Lomb Americas Inc. | 1 | $72 |
| Astellas Pharma US Inc | 1 | $27 |
| Shire North American Group Inc | 1 | $27 |
| Fisher & Paykel Healthcare Inc | 1 | $24 |
| Maculogix, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FORUM$654
- CEQUA$376
- QUATERA 700$350
- CALLISTO eye$350
- CIRRUS HD-OCT$350
- CIRRUS 6000 with AngioPlex$350
- RESTASIS$250
- Oxervate$240
- Rhopressa$235
- Rocklatan$235
- LUMIGAN$226
- RXSIGHT CONTACT LENS$131
- RXSIGHT INJECTOR CARTRIDGE$131
- RXSIGHT INJECTOR HANDPIECE$131
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$131
- LIGHT ADJUSTABLE LENS (LAL)$131
- TYRVAYA$125
- EYLEA$124
- Acuvue$124
- Clareon$122
How this compares
$6,371 in reported general payments places this provider in the 90th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 89 | $126,461 |
| XiidraLifitegrast | 22 | $42,536 |
| LumiganBimatoprost | 49 | $23,781 |
| CombiganBrimonidine Tartrate/Timolol | 40 | $14,925 |
| Cyclosporine | 19 | $11,630 |
| Alphagan PBrimonidine Tartrate | 27 | $10,470 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 66 | $7,106 |
| Latanoprost | 448 | $3,565 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $3,107 |
| Travoprost | 24 | $2,294 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 177 | $2,278 |
| Prednisolone Acetate | 54 | $2,270 |
| Fluorometholone | 25 | $1,322 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 77 | $972 |
| Azelastine Hcl | 39 | $951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $606 | $175,636205 claims |
| Bausch & Lomb Americas Inc.Xiidra | $72 | $42,53622 claims |
| AlconSimbrinza | $473 | $3,10714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,315 optometrist providers in Texas.
Other optometrist in El Paso
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Mina VanrachackSan Antonio$553K
- Luis RojasMcKinney$309K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.